1.Sloan M, Premkumar A, Sheth NP: Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am 2018, 100(17):1455–1460.
2.Lieberman JR, Cheng V, Cote MP: Pulmonary Embolism Rates Following Total Hip Arthroplasty with Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided. The Journal of arthroplasty 2017, 32(3):980–986.
3.Cote MP, Chen A, Jiang Y, Cheng V, Lieberman JR: Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even with Prophylactic Anticoagulants. The Journal of arthroplasty 2017, 32(12):3833–3839.
4.Warren JA, Sundaram K, Kamath AF, Molloy RM, Krebs VE, Mont MA, Piuzzi NS: Venous Thromboembolism Rates Did Not Decrease in Lower Extremity Revision Total Joint Arthroplasty From 2008 to 2016. The Journal of arthroplasty 2019.
5.Dai WL, Lin ZM, Shi ZJ, Wang J: Venous Thromboembolic Events after Total Knee Arthroplasty: Which Patients Are at a High Risk? The journal of knee surgery 2019.
6.Dastrup A, Pottegard A, Hallas J, Overgaard S: Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death After Total Hip Arthroplasty: A Population-Based Cohort Study from National Danish Databases. J Bone Joint Surg Am 2018, 100(20):1742–1749.
7.Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW, Jr.: Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl): e278S-e325S.
8.Parvizi J, Huang R, Raphael IJ, Maltenfort MG, Arnold WV, Rothman RH: Timing of Symptomatic Pulmonary Embolism with Warfarin Following Arthroplasty. J Arthroplasty 2015, 30(6):1050–1053.
9.Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, Bellosta S: Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacological research 2018, 135:60–79.
10.Mirkazemi C, Bereznicki LR, Peterson GM: Comparing Australian orthopaedic surgeons’ reported use of thromboprophylaxis following arthroplasty in 2012 and 2017. BMC musculoskeletal disorders 2019, 20(1):57.
11.Kim S, Ahn H, Shin SA, Park JH, Won CW: Trends of thromboprophylaxis and complications after major lower limb orthopaedic surgeries in Korea: National Health Insurance Claim Data. Thrombosis research 2017, 155:48–52.
12.Bohl DD, Ondeck NT, Basques BA, Levine BR, Grauer JN: What Is the Timing of General Health Adverse Events That Occur After Total Joint Arthroplasty? Clin Orthop Relat Res 2017, 475(12):2952–2959.
13.Johnson DJ, Hartwell MJ, Weiner JA, Hardt KD, Manning DW: Which Postoperative Day After Total Joint Arthroplasty Are Catastrophic Events Most Likely to Occur? The Journal of arthroplasty 2019.
14.Parvizi J, Mui A, Hozack WJ, Rothman RH, Sharkey PF: Total Joint Arthroplasty: When Do Fatal or Near-Fatal Complications Occur? Journal of Arthroplasty 2006, 21(2):27.
15.Beyth RJ, Milligan PE, Gage BF: Risk factors for bleeding in patients taking coumarins. Curr Hematol Rep 2002, 1(1):41–49.
16.Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE: Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages. American Journal of Medicine 2007, 120(8):700–705.
17.Liu J, Jiang HH, Wu DK, Zhou YX, Ye HM, Li X, Luo ZY, Guo Z, Zhang YL, Wang YC et al: Effect of gene polymorphims on the warfarin treatment at initial stage. The pharmacogenomics journal 2017, 17(1):47–52.
18.Karcutskie CA, Dharmaraja A, Patel J, Eidelson SA, Padiadpu AB, Martin AG, Lama G, Lineen EB, Namias N, Schulman CI et al: Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. JAMA surgery 2018, 153(2):144–149.
19.Alves C, Batel-Marques F, Macedo AF: Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-Analysis. J Cardiovasc Pharmacol Ther 2012, 17(3):266–276.
20.Zhao X, Sun P, Zhou Y, Liu Y, Zhang H, Mueck W, Kubitza D, Bauer RJ, Zhang H, Cui Y: Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. British Journal of Clinical Pharmacology 2010, 68(1):77–88.
21.Morda M, Pini S, Celli F, Casella F, Parchi P, Piolanti N, Marchetti S, Scaglione M: Bone cement implantation syndrome: a thromboelastographic study of the effect of bone cement on coagulation. Journal of biological regulators and homeostatic agents 2017, 31(4 suppl 1):121–127.
22.Martinelli I, Bucciarelli P, Mannucci PM: Thrombotic risk factors: basic pathophysiology. Critical Care Medicine 2010, 38(2 Suppl): S3–9.
23.Kashuk JL, Moore EE, Sabel A, Barnett C, Haenel J, Le T, Pezold M, Lawrence J, Biffl WL, Cothren CC: Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery 2009, 146(4):764–774.
24.Sikorski JM, Hampson WG, Staddon GE: The natural history and aetiology of deep vein thrombosis after total hip replacement. Journal of Bone & Joint Surgery British Volume 1981, 63-B (2):171.
25.Yamaguchi T, Hasegawa M, Niimi R, Sudo A: Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty. Thrombosis research 2010, 126(4):e323–326.
26.Schotanus MGM, Bemelmans YFL, Grimm B, Heyligers IC, Kort NP: Physical activity after outpatient surgery and enhanced recovery for total knee arthroplasty. Knee surgery, sports traumatology, arthroscopy: official journal of the ESSKA 2017, 25(11):3366–3371.
27.S L, JI H, Y K, PW Y, J A, JJ Y: Venous Thromboembolism Following Hip and Knee Replacement Arthroplasty in Korea: A Nationwide Study Based on Claims Registry. Journal of Korean medical science 2016, 31(1):80–88.
28.Parvizi J, Huang R, Raphael IJ, Arnold WV, Rothman RH: Symptomatic Pulmonary Embolus After Joint Arthroplasty: Stratification of Risk Factors. Clin Orthop Relat Res 2014, 472(3):903–912.
29.P M, M S, M C, G F, F C, G G, G T, I L, G R, F C et al: Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship? Aging clinical and experimental research 2018.
30.Lip GY: Does atrial fibrillation confer a hypercoagulable state? Lancet 1995, 346(8986):1313–1314.
31.Kahn SR, Solymoss S, Flegel KM: Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne 1997, 157(6):673–681.
32.Ozcan M, Erem M, Turan FN: Symptomatic Deep Vein Thrombosis Following Elective Knee Arthroscopy Over the Age of 40. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2019, 25:1076029619852167.
33.Mendez GM, Patel YM, Ricketti DA, Gaughan JP, Lackman RD, Kim TWB: Aspirin for Prophylaxis Against Venous Thromboembolism After Orthopaedic Oncologic Surgery. Journal of Bone & Joint Surgery-american Volume 2017, 99(23):2004–2010.
34.Tala JA, Silva CT, Pemira S, Vidal E, Faustino EVS: Blood glucose as a marker of venous thromboembolism in critically ill children. Journal of Thrombosis & Haemostasis 2014, 12(6):891–896.
35.Stegenga ME, van der Crabben SN, Blumer RME, Levi M, Meijers JCM, Serlie MJ, Tanck MWT, Sauerwein HP, van der Poll T: Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008, 112(1):82–89.
36.Ferroni P, Basili S, Falco A, Davi G: Platelet activation in type 2 diabetes mellitus. Journal of thrombosis and haemostasis: JTH 2004, 2(8):1282–1291.